FierceBiotech

ProFibrix Initiates Phase II With Lead Hemostasis Product Fibrocaps(TM) in US and Europe

LEIDEN, The Netherlands and SEATTLE, March 8, 2011 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has initiated a ...
FierceBiotech

ProFibrix Completes Enrollment of Phase II Studies with Lead Hemostasis Product FibrocapsTM and Targets Start of Pha

LEIDEN, The Netherlands & SEATTLE--(BUSINESS WIRE)-- ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its ...
Monthly Prescribing Reference

Phase 2 Study of Fibrocaps for Hemostasis

ProFibrix announced initiation of its Phase 2 study of Fibrocaps for use as a hemostatic agent in surgery. This prospective, randomized, multicenter, single-blind, controlled study will evaluate the ...
BioWorld

ProFibrix Starts Phase III Trial Of FibroCaps in Hemostasis

LONDON – ProFibrix BV has moved swiftly from Phase II development and treated the first patients in the Phase III trial of its hemostasis product FibroCaps, less than four months after meeting with ...
Monthly Prescribing Reference

Phase 3 Study Update of 4-Factor Prothrombin Complex Concentrate for Hemostasis

CSL Behring announced results of a Phase 3b study that showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping ...
Nature

Neonatal platelets: mediators of primary hemostasis in the developing hemostatic system

The hemostatic system is maintained by a delicate balance of pro- and anticoagulant factors, allowing for physiologic response to hemorrhage while simultaneously avoiding development of pathologic ...